Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TollB-001 Phase 1 SAD/MAD and Food Effect Study in Healthy Adults
NCT06103773Phase 1Completed
- Sponsor
- Toll Biotech Co., Ltd.
- Start
- Sep 2023
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of tollb-001 in rheumatoid arthritis (RA) (11 arms), sponsored by Toll Biotech Co., Ltd. Primary endpoints: Red blood cell count up to 3.5 weeks, Hematocrit up to 3.5 weeks and 36 more. Started Sep 2023; status: completed.
02
Drugs
tollb-001
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06103773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06103773.